Foralumab

Drug Profile

Foralumab

Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Medarex; NovImmune SA
  • Developer NovImmune SA; Tiziana Life Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I Non-alcoholic steatohepatitis; Primary biliary cirrhosis
  • Preclinical Inflammatory bowel diseases; Type 2 diabetes mellitus
  • Discontinued Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 19 Jun 2017 Tiziana Life Sciences plans phase II trials for Non-alcoholic steatohepatitis and Primary biliary cirrhosis (PO) (Tiziana Life Sciences Pipeline, June 2017)
  • 12 Jun 2017 Phase-I clinical trials in Non-alcoholic steatohepatitis (PO) before June 2017 (Tiziana Life Sciences Pipeline, June 2017)
  • 12 Jun 2017 Phase-I clinical trials in Primary biliary cirrhosis (PO) before June 2017 (Tiziana Life Sciences Pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top